AIT Therapeutics’ nitric oxide mist led to a 65 percent reduction in cystic fibrosis patients’ airway bacteria and an improvement in their exercise capability 60 days after treatment, a Phase 2 clinical trial shows. The bacteria that the nitric oxide countered was the Mycobacterium abscessus complex. The exercise-capability yardstick researchers…
News
Changes in bacteria present in the lower respiratory tract during the first years of life may be indicative of early progression of lung disease in cystic fibrosis (CF) patients, according to researchers at the University of North Carolina School of Medicine. The finding was reported in the study, “…
A therapy whose developers say could revolutionize the battle against antibiotic-resistant lung infections in cystic fibrosis patients eliminated resistant Staphylococcus aureus in a lab, a study reports. The finding dealt with Synspira’s polycationic glycopolymer SNSP113 as a stand-alone treatment. The study also showed that the therapy increased the punch of antibiotics used to counter…
Dr. Beth A. Smith with the University at Buffalo has received a mental healthcare award from the Cystic Fibrosis Foundation for her work in advancing the understanding and care of mental health in cystic fibrosis — regarding both the prevalence of depression among patients and its impact on…
Motif Bio has received a $120,000 award from the Cystic Fibrosis Foundation (CFF) to fund in vitro testing of iclaprim — a broad-spectrum antibiotic — for the treatment of lung infections in people with cystic fibrosis (CF). Iclaprim is an antibiotic with potent in vitro activity against Gram-positive…
It takes only slightly longer to deliver an inhaled therapy in cystic fibrosis (CF) patients sitting upright than when lying alternately on either side, according to an Australian study. Usually, doctors have patients sit upright when inhaling nebulized medications in order to maximize the lung’s volume. However, experts say distribution patterns…
A study in young children with cystic fibrosis (CF) shows that low chest radiograph scores are associated with more frequent pulmonary exacerbations, and the use of antibiotics is beneficial when respiratory symptoms increase. Although it’s been established that pulmonary exacerbations lead to a decline in lung function in older children and…
Using a cystic fibrosis patient’s tissue to grow mini-guts in a lab has become easier and is available to more scientists who want to use it both to study the disease and test patients’ response to therapies. Stemcell Technologies, a Canadian biotechnology company, has released two new lines…
ProQR Therapeutics and Galapagos are working together on a new approach to treating the tissue scarring seen in cystic fibrosis. The collaboration will take advantage of ProQR’s proprietary next-generation RNA technology to develop axiomer editing oligonucleotides that can fight the fibrosis-promoting agents Galapagos has identified. “In this collaboration we…
Celtaxsys has obtained financing for a Phase 3 clinical trial of acebilustat as a treatment for cystic fibrosis. Acebilustat inhibits an enzyme that takes part in the production of a substance called leukotriene B4 (LTB4) that promotes an immune response known as inflammation. Scientists believe LTB4 plays a key role…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.